

Special Issue

Molecular Basis and Therapeutics of Neurodegenerative Diseases

Message from the Guest Editor

Neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS, pose a growing global health challenge, yet their molecular mechanisms remain understood. Recent advances highlight the roles played by protein misfolding, mitochondrial dysfunction, neuroinflammation, and extracellular vesicles (EVs) in disease progression. EVs are emerging as key players in intercellular communication, carrying pathological proteins and nucleic acids that may serve as biomarkers or therapeutic targets. This Special Issue welcomes the submission of both reviews and original articles exploring cutting-edge research on the molecular mechanisms driving neurodegeneration and innovative therapeutic strategies, from gene therapies to EV-based interventions.

Guest Editor

Dr. Tânia Soares Martins

Neuroscience and Signalling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal

Deadline for manuscript submissions

closed (15 May 2026)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/233730

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))